JP7121660B2 - 癌を処置するためのｅｚｈ２阻害剤の使用 - Google Patents

癌を処置するためのｅｚｈ２阻害剤の使用 Download PDF

Info

Publication number
JP7121660B2
JP7121660B2 JP2018562564A JP2018562564A JP7121660B2 JP 7121660 B2 JP7121660 B2 JP 7121660B2 JP 2018562564 A JP2018562564 A JP 2018562564A JP 2018562564 A JP2018562564 A JP 2018562564A JP 7121660 B2 JP7121660 B2 JP 7121660B2
Authority
JP
Japan
Prior art keywords
alkyl
cancer
linker
halo
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018562564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517491A (ja
JP2019517491A5 (enExample
Inventor
リビチ スコット
ソメニウス マイケル
Original Assignee
エピザイム，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピザイム，インコーポレイティド filed Critical エピザイム，インコーポレイティド
Publication of JP2019517491A publication Critical patent/JP2019517491A/ja
Publication of JP2019517491A5 publication Critical patent/JP2019517491A5/ja
Application granted granted Critical
Publication of JP7121660B2 publication Critical patent/JP7121660B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018562564A 2016-06-01 2017-06-01 癌を処置するためのｅｚｈ２阻害剤の使用 Active JP7121660B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344338P 2016-06-01 2016-06-01
US62/344,338 2016-06-01
PCT/US2017/035391 WO2017210395A1 (en) 2016-06-01 2017-06-01 Use of ezh2 inhibitors for treating cancer

Publications (3)

Publication Number Publication Date
JP2019517491A JP2019517491A (ja) 2019-06-24
JP2019517491A5 JP2019517491A5 (enExample) 2020-07-09
JP7121660B2 true JP7121660B2 (ja) 2022-08-18

Family

ID=60477941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018562564A Active JP7121660B2 (ja) 2016-06-01 2017-06-01 癌を処置するためのｅｚｈ２阻害剤の使用

Country Status (6)

Country Link
US (2) US11786533B2 (enExample)
EP (1) EP3464643A4 (enExample)
JP (1) JP7121660B2 (enExample)
AU (1) AU2017273726B2 (enExample)
CA (1) CA3025933A1 (enExample)
WO (1) WO2017210395A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
CN110898067A (zh) 2012-10-15 2020-03-24 Epizyme股份有限公司 癌症治疗方法
JP7121660B2 (ja) 2016-06-01 2022-08-18 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
WO2017218953A1 (en) 2016-06-17 2017-12-21 Epizyme, Inc. Ezh2 inhibitors for treating cancer
EP3548032A2 (en) * 2016-12-02 2019-10-09 Epizyme, Inc. Combination therapy for treating cancer
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2019050924A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
WO2019152419A1 (en) 2018-01-31 2019-08-08 Mirati Therapeutics, Inc Prc2 inhibitors
WO2019241742A1 (en) * 2018-06-14 2019-12-19 Board Of Regents, The University Of Texas System Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
JP7624404B2 (ja) 2019-04-22 2025-01-30 ミラティ セラピューティクス，インク． Ｐｒｃ２阻害剤としてのナフチリジン誘導体
WO2020247475A1 (en) 2019-06-05 2020-12-10 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
TW202114663A (zh) * 2019-09-30 2021-04-16 大陸商江蘇恒瑞醫藥股份有限公司 EZH2抑制劑與含有TGF-β受體的融合蛋白聯合在製備治療腫瘤的藥物中的用途
KR102505664B1 (ko) * 2019-10-31 2023-03-03 재단법인 대구경북첨단의료산업진흥재단 Ezh2 저해제　및　e3 리가제 바인더를 포함하는 화합물 및 이를 유효성분으로 함유하는 ezh2 관련 질환의 예방 또는 치료용 약학적 조성물
CN111303133A (zh) * 2020-03-25 2020-06-19 清华大学 降解ezh2蛋白的小分子化合物
JP2024500975A (ja) * 2020-12-23 2024-01-10 カスケード プロドラッグ インコーポレイテッド ビンカアルカロイドｎ－オキシドと免疫チェックポイント阻害剤との併用療法
WO2024138655A1 (zh) * 2022-12-30 2024-07-04 清华大学 药物组合物及其应用
WO2024238381A1 (en) * 2023-05-12 2024-11-21 Taipei Medical University Dual ezh2-hsp90 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522045A (ja) 2015-08-03 2018-08-09 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｅｚｈ２阻害剤および制御性ｔ細胞機能の調節

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2482903A (en) * 2010-08-19 2012-02-22 Software Imaging Technology Ltd A print engine
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US9175331B2 (en) * 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
TR201904660T4 (tr) 2012-03-12 2019-05-21 Epizyme Inc İnsan EZH2 inhibitörleri ve bunun kullanım yöntemleri.
IL308807B2 (en) * 2012-04-13 2025-08-01 Epizyme Inc Combination therapy for treating cancer
DK3184523T3 (da) 2012-04-13 2019-08-19 Epizyme Inc N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4' -(morphofinomethyl)-[1,1'-biphenyl]-3-carboxamidhydrobromid til anvendelse i behandlingen af en sygdom med celleproliferation i det hæmatologiske system.
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
DE112012006784B4 (de) * 2012-08-06 2019-05-09 Avago Technologies International Sales Pte. Ltd. Vorrichtungen, Verfahren und Computerprogrammprodukte bezüglich Verbesserungen in Mechanismen zur Verhinderung einer autonomen Ablehnung
US20140062720A1 (en) * 2012-09-06 2014-03-06 John Murray Spruth Remote Pipeline Corrosion Protection and Valve Monitoring Apparatus
CN110898067A (zh) 2012-10-15 2020-03-24 Epizyme股份有限公司 癌症治疗方法
PE20150886A1 (es) 2012-10-15 2015-06-04 Epizyme Inc Compuestos de benceno sustituidos
US20150283142A1 (en) * 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20150313906A1 (en) * 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
AU2013361079B2 (en) 2012-12-21 2018-07-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
US20150344427A1 (en) 2012-12-21 2015-12-03 Epizyme, Inc. 1,4-pyridone compounds
EP2970281A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BENZOL COMPOUNDS
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
EP2981821B2 (en) 2013-04-02 2021-11-03 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
US9624205B2 (en) 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015010049A1 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
SG11201602269QA (en) 2013-10-16 2016-04-28 Epizyme Inc Hydrochloride salt form for ezh2 inhibition
US20160228447A1 (en) 2013-10-18 2016-08-11 Epizyme, Inc. Method of treating cancer
CN116019921A (zh) 2013-12-06 2023-04-28 Epizyme股份有限公司 用于治疗癌症的组合疗法
WO2015160986A2 (en) * 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
PL3157527T3 (pl) 2014-06-17 2023-08-07 Epizyme, Inc. Inhibitory ezh2 do leczenia chłoniaka
WO2015200650A1 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
CN106794177A (zh) 2014-10-16 2017-05-31 Epizyme股份有限公司 治疗癌症的方法
BR112017010166A2 (en) 2014-11-17 2018-02-14 Epizyme, Inc. solid tumor treatment method, activity inhibition method, oral dosage form for treating a solid tumor, solid pharmaceutical formulation, process for preparing a pharmaceutical formulation, and solid pharmaceutical composition
HRP20190805T1 (hr) 2014-12-23 2019-06-28 Novartis Ag Spojevi triazolopirimidina i njihova uporaba
CN108135908A (zh) 2015-04-20 2018-06-08 Epizyme股份有限公司 用于治疗癌症的组合疗法
JP6890097B2 (ja) 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
CA2996412A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
CA2999898A1 (en) 2015-09-25 2017-03-30 Epizyme, Inc. Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type (sccoht) with an ezh2 inhibitor
SG10201909413SA (en) 2015-10-06 2019-11-28 Epizyme Inc Method of treating medulloblastoma with an ezh2 inhibitor
US20190070188A1 (en) 2015-11-06 2019-03-07 Epizyme, Inc. Pediatric dosing for treatment of cancer with an ezh2 inhibitor
EP3386513A2 (en) 2015-12-07 2018-10-17 Epizyme Inc Inhibitors of ezh2 and methods of use thereof
CA3011186A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
JP2019508406A (ja) 2016-02-08 2019-03-28 エピザイム，インコーポレイティド 癌を処置する方法
JP7121660B2 (ja) 2016-06-01 2022-08-18 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
WO2017218953A1 (en) 2016-06-17 2017-12-21 Epizyme, Inc. Ezh2 inhibitors for treating cancer
EP3548032A2 (en) 2016-12-02 2019-10-09 Epizyme, Inc. Combination therapy for treating cancer
WO2018144798A1 (en) 2017-02-02 2018-08-09 Epizyme, Inc. Cancer treatment modalities
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522045A (ja) 2015-08-03 2018-08-09 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｅｚｈ２阻害剤および制御性ｔ細胞機能の調節

Also Published As

Publication number Publication date
AU2017273726A1 (en) 2018-12-06
US11786533B2 (en) 2023-10-17
WO2017210395A1 (en) 2017-12-07
US20240139203A1 (en) 2024-05-02
EP3464643A1 (en) 2019-04-10
EP3464643A4 (en) 2020-04-01
AU2017273726B2 (en) 2023-10-19
US20220288085A1 (en) 2022-09-15
JP2019517491A (ja) 2019-06-24
CA3025933A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
JP7121660B2 (ja) 癌を処置するためのｅｚｈ２阻害剤の使用
US11951109B2 (en) EZH2 inhibitors for treating lymphoma
JP2023071905A (ja) 癌を処置するためのｅｚｈ２阻害剤
JP2023095928A (ja) 癌を処置するためのｅｚｈ２阻害剤の使用
US20220160721A1 (en) Methods of treating cancer
JP6779793B2 (ja) リンパ腫を治療するためのｅｚｈ２阻害剤
JP2024001203A (ja) 癌を処置するための併用療法
JP2018062535A (ja) ガンの治療方法
JP2019503391A (ja) 癌を処置するための併用療法
TR201807023T4 (tr) Abl1, abl2 ve bcr- abl1 aktivitesinin inhibe edilmesi için benzamid türevleri.
JP2018513865A (ja) 癌を処置するための併用療法
JP2023026523A (ja) 癌処置様式
CN108025191A (zh) 治疗癌症的方法
WO2017097215A1 (zh) 内嵌脲类结构的wnt通路抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220805

R150 Certificate of patent or registration of utility model

Ref document number: 7121660

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150